Rituximab News and Research

RSS

Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.

Research highlights emergence of immune-evasive SARS-CoV-2 variants in immunocompromised patients

New research to be presented at next week's ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April) highlights the risk of new immune-evasive SARS-CoV-2 variants emerging in immunocompromised patients.

18 Apr 2024

Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers

Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors.

10 Apr 2024

Therapeutic potential of CD20 x CD3 bispecific antibodies

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.

From Sino Biological Inc. 5 Apr 2024

Study reveals safety of MS drugs during breastfeeding in child's early years of life

Certain medications for multiple sclerosis (MS) called monoclonal antibodies, taken while breastfeeding, may not affect the development of a child during the first three years of life, according to a preliminary study released today, March 4, 2024.

4 Mar 2024

Study offers insights into who's at risk for long COVID among immunocompromised patients

Early in the pandemic, clinicians noticed that certain immunocompromised patients were experiencing persistent SARS-CoV-2 infections, some lasting weeks to months at a time.

26 Jan 2024

Mice with humanized immune systems test new cancer therapeutic approach that blindfolds immune cells to the body’s self-recognition system

Researchers investigated the anticancer effects of drugs targeting human tumor-associated macrophages (TAMs) in vivo. In humanized murine models, they tested the effectiveness of an antibody to human signal regulatory protein alpha (SIRPα) for cancer immunotherapy.

19 Dec 2023

T-cells step up to offer protection against COVID-19 in B-cell deficient patients

B cell deficiency is a common condition that can result either from immunosuppressant drugs used to treat autoimmune disease or certain cancers -; such as rituximab (RTX) -; or from natural immune deficiency.

18 Dec 2023

Researchers develop humanized mouse model for macrophage-targeted cancer immunotherapy

Mice with human immune cells are a new way of testing anti-cancer drugs targeting the immune system in pre-clinical studies.

14 Dec 2023

New combination treatment offers hope for older patients with mantle cell lymphoma

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting.

11 Dec 2023

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a 'surprisingly high' response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma.

11 Dec 2023

Research redefines rheumatoid arthritis: Over 314,000 cells analyzed for precise treatment strategies

A new paper recently published in Nature, reported the examination of synovial tissue from the joints of nearly 80 people with RA, in combination with RNA sequencing and surface protein analyses.

10 Nov 2023

Study provides evidence for combination therapy as first-line treatment for relapsed ITP

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, conducted a multicenter comprehensive retrospective analysis to assess the effectiveness and safety of primary single-agent and combination therapies in treating adult patients with relapsed immune thrombocytopenia (ITP).

9 Oct 2023

Phase 1 clinical trial underway to test City of Hope-developed cancer treatment

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research.

1 Aug 2023

Are antidrug antibodies reducing the effectiveness of rheumatoid arthritis treatment?

Researchers examined the association between antidrug antibodies and the response to treatments for rheumatoid arthritis.

17 Jul 2023

Vaccination protects lupus patients from contracting COVID-19

Researchers determine the risk of COVID-19 and possibility of severe sequelae in patients with systemic lupus erythematosus and the general population.

14 Mar 2023

COVID-19 outcomes in Rituximab treated patients

A new report throws light on SARS-CoV-2 breakthrough infections in patients with certain joint diseases or musculoskeletal conditions who are on rituximab and compares the severity of COVID-19 outcomes in these patients whilst identifying potential risk factors for severe outcomes.

11 Jan 2023

Research suggests people on rheumatoid arthritis drugs show weaker response to SARS-CoV-2 vaccines

Researchers conducted a comparative study among a cohort of individuals on rheumatoid arthritis (RA) therapies vis-à-vis healthy controls to assess their responses to coronavirus disease 2019 (COVID-19) vaccines.

9 Jan 2023

Major treatment advance revealed for adults with newly diagnosed B lineage acute lymphoblastic leukemia

Late-breaking research reveals a major treatment advance for adults with newly diagnosed B lineage acute lymphoblastic leukemia (ALL).

14 Dec 2022

Additional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patients

A third COVID-19 vaccine dose in this patients with blood cancers could enhance their antibody responses against SARS-CoV-2

21 Nov 2022

Higher dose of pneumococcal vaccine improves antibody response in patients receiving rituximab for ANCA-associated vasculitis

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that a higher dose of pneumococcal vaccine safely and effectively improved antibody response in patients receiving rituximab for ANCA-associated vasculitis.

8 Nov 2022